Herpes simplex virus inhibitor - CytoGenix
Alternative Names: CY-301; CYGpssXE-59; SimplivirLatest Information Update: 04 Nov 2017
At a glance
- Originator CytoGenix
- Class DNA
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Herpes simplex virus infections
Highest Development Phases
- No development reported Herpes simplex virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (Topical, Cream)
- 10 Jan 2008 This programme is still in active development
- 04 Mar 2005 Preclinical data from a media release have been added to the Viral infections pharmacodynamics section